secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001104659-25-024731
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Pharma reports FY 2024 net loss $14.1M; cash $3.7M; EMA guidance for Phase 3
--------------------------------------------------------------------------------

- Net loss Q4 2024 $2.8M ($0.16/diluted share) vs $5.1M ($0.37) in Q4 2023; FY 2024 net loss $14.1M ($0.87) vs $14.6M ($1.15).
- Cash at Dec 31, 2024: $3.7M, down from $7.5M; raised $6.6M via ATM in 2024 plus $3.6M in direct offerings in early 2025.
- Positive EMA guidance for ibezapolstat Phase 3 program aligned with FDA; regulatory pathway for MAA after Phase 3 completion.
- Japan patent granted for DNA pol IIIC inhibitors (expires 2039); advancing ACX-375C for MRSA/VRE/Anthrax.
- Phase 2 data: 96% clinical cure, 100% sustained cure at 1 month; non-clinical studies show microbiome-restorative potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465925024731/0001104659-25-024731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465925024731/tm259528d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-024731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer